Cencora, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Cencora restated segment reporting for fiscal years 2026 and 2025 across three segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. FY2026 total revenue revised to $337.4B (vs. FY2025: $321.3B), with operating income of $4.8B in FY2026 (vs. $4.2B in FY2025). The filing provides revised quarterly and annual figures but does not explain the reason for the restatement or quantify the magnitude of revisions from prior disclosures.
Why this rating
Administrative segment restatement with no stated business impact. Magnitudes ($16B revenue growth) are normal for $37.9B company; no explanation of restatement cause provided—appears routine reclassification.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.